Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...

About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey ...

GLP-1 agonist users had a 17% lower cancer risk compared to non-users in a large retrospective study. The reductions achieved ...

Eli Lilly (NYSE:LLY) announced on Tuesday that its oral weight loss therapy, orforglipron, reached the main goals in a second ...

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals Inc.’s lead investigational candidate, currently in clinical ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences.

Muscle pairings are agonists and antagonists. Agonists are the primary working muscle during an exercise and antagonists are the relaxed muscle. A personal trainer explains all.